Moxetumomab pasudotox is a second-generation recombinant immunotoxin against CD22 on B-cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy-refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient-derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD-scid IL2Rg mice showed a modest survival benefit in mice engrafted with 697 cells but not in NALM6 or the two patient-derived xenograft models.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501879 | PMC |
| http://dx.doi.org/10.1002/pbc.26604 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hairy cell leukemia variant and WHO classification correspondence Re: 5 edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
Leukemia
July 2024
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico "Sant'Orsola-Malpighi", and Department of Medical and Surgical Sciences - University of Bologna, Bologna, Italy.
Unusual presentation of gastric cancer during treatment of hairy cell leukemia: Exploring the etiological basis of this rare phenomenon.
Cancer Pathog Ther
April 2023
Department of Hematology/Oncology, Regional Medical Center (RMC), Anniston, AL, 36207, USA.
Article Synopsis
- Hairy cell leukemia (HCL) is a rare type of blood cancer that affects certain white blood cells and can cause problems like low blood cell counts and an enlarged spleen.
- A 78-year-old patient with HCL developed a cyst on their back while undergoing a specific treatment called moxetumomab pasudotox.
- A biopsy of the cyst showed it was actually cancer from the stomach (stage IV gastric cancer), but more research is needed to see if the treatment is linked to getting this other cancer.
Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.
Int J Clin Pharm
June 2024
Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, 10# Zhenhai Road, Xiamen, China.
Background: Antibody-drug conjugates have revolutionized cancer therapy due to their selectivity and efficacy. However, concerns have been raised regarding the potential effects of trastuzumab deruxtecan in interstitial lung diseases.
Aim: This study aimed to investigate the safety signals and time to onset of antibody-drug conjugates induced interstitial lung disease.
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers: anaplastic thyroid carcinoma (n = 36), biliary tract cancer (n = 43), gastrointestinal stromal tumor (n = 1), adenocarcinoma of the small intestine (n = 3), low-grade glioma (n = 13), high-grade glioma (n = 45), hairy cell leukemia (n = 55) and multiple myeloma (n = 19). The primary endpoint of investigator-assessed overall response rate in these cohorts was 56%, 53%, 0%, 67%, 54%, 33%, 89% and 50%, respectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!